Anavex Life Sciences Stock Earnings Reports

Anavex reported Q2 FY2025 operational and financial updates. Clinically, the company highlighted open-label extension data for oral blarcamesine (ANAVEX2-73) showing continued, clinically meaningful benefit in early Alzheimer's disease over three to four years on ADAS-Cog13 and ADCS-ADL endpoints. The company submitted files to the EMA in November (accepted in December) and expects regulatory feedback in roughly a 12-month window (potentially by year-end/early next year). Commercial readiness activities are underway (partnering discussions and CRO/sales options) and the company reports manufacturing inventory in place. In schizophrenia, Anavex completed enrollment in the Phase 2 ANAVEX3-71 trial (71 participants total; Part B is a 28-day randomized period) and expects top-line data in the second half of 2025. Corporate governance/science was bolstered by adding Prof. Audrey Gabelle to the Scientific Advisory Board. Financially, cash was $115.8M at March 31 with no debt, quarterly operating cash use of $5.9M, and an estimated cash runway of approximately four years; Q2 R&D was $9.9M, G&A $2.6M, and net loss $11.2M ($0.13/share). Key near-term investor milestones: EMA feedback/decision timing, H2 2025 schizophrenia top-line data, and potential commercialization or partnership decisions contingent on regulatory outcomes.